Functionally selective signaling and broad metabolic benefits by novel insulin receptor partial agonists

Insulin analogs have been developed to treat diabetes with focus primarily on improving the time action profile without affecting ligand-receptor interaction or functional selectivity. As a result, inherent liabilities (e.g. hypoglycemia) of injectable insulin continue to limit the true therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Margaret, Carballo-Jane, Ester, Zhou, Haihong, Zafian, Peter, Dai, Ge, Liu, Mindy, Lao, Julie, Kelly, Terri, Shao, Dan, Gorski, Judith, Pissarnitski, Dmitri, Kekec, Ahmet, Chen, Ying, Previs, Stephen F., Scapin, Giovanna, Llorente, Yacob Gomez, Hollingsworth, Scott A., Yan, Lin, Feng, Danqing, Huo, Pei, Walford, Geoffrey, Erion, Mark D., Kelley, David E., Lin, Songnian, Mu, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854621/
https://www.ncbi.nlm.nih.gov/pubmed/35177603
http://dx.doi.org/10.1038/s41467-022-28561-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854621/
https://www.ncbi.nlm.nih.gov/pubmed/35177603
http://dx.doi.org/10.1038/s41467-022-28561-9

Ejemplares similares